Core Viewpoint - Sartorius reported a sales revenue of €2.611 billion for the first nine months of 2025, reflecting a year-on-year growth of 7.5%, driven primarily by the bioprocess solutions segment [3][4]. Group 1: Financial Performance - The sales revenue for the bioprocess solutions segment reached €2.115 billion, with a year-on-year increase of 9.9%, while the laboratory products and services segment saw a decline of 1.3%, totaling €495 million [3][4]. - Basic EBITDA increased by 12.8% year-on-year to €774 million, with a profit margin rising to 29.7%, up from 27.7% in the previous year [5]. - Basic net profit grew by 17.0% year-on-year to €244 million, with earnings per share for common stock rising to €3.52 [5]. Group 2: Business Development - The bioprocess solutions segment accounted for over 75% of total sales revenue, achieving a significant growth of 9.9% year-on-year, primarily due to strong demand for high-margin single-use consumables [7][8]. - The laboratory products and services segment experienced a slight decline in sales revenue of 1.3% year-on-year, but showed signs of recovery, aided by the acquisition of MATTEK, which contributed nearly 1 percentage point to revenue growth [9][10]. Group 3: Market Outlook and Guidance - The company has raised its full-year sales revenue growth forecast to approximately 7%, up from the previous estimate of around 6% organic growth [3][10]. - The bioprocess solutions segment is expected to achieve around 9% growth, while the laboratory products and services segment is projected to remain flat compared to the previous year [10][11]. - The management anticipates that the basic EBITDA margin will be slightly above 29.5% for the group, with the bioprocess solutions segment expected to exceed 31.5% [11].

Core Viewpoint - Sartorius reported a sales revenue of €1.767 billion for the first half of 2025, marking a year-on-year growth of 6.1%, primarily driven by the bioprocess solutions segment and laboratory products and services [3][4]. Group 1: Financial Performance - The company achieved a sales revenue growth of 6.1% in the first half of 2025 [4]. - The bioprocess solutions segment generated €1.435 billion, with a year-on-year growth of 8.8% [4]. - The laboratory products and services segment reported a revenue of €332 million, showing a decline of 4.0% when adjusted for fixed exchange rates [5]. Group 2: Business Segments - The bioprocess solutions segment is expected to grow approximately 7% for the full year 2025, supported by a rich product portfolio that enhances drug production efficiency [6]. - The laboratory products and services segment is projected to grow about 1% for the full year 2025, with new products aimed at accelerating drug development [6]. Group 3: Management Outlook - The management confirmed the full-year guidance for 2025, anticipating an organic sales revenue growth of around 6% [6]. - The CEO expressed satisfaction with the first half performance and emphasized the importance of high-margin consumables in the pharmaceutical sector [4].